Cjc-1295 No Dac Research Peptide

Molecular Structure and Chemical Profile of CJC-1295 No DAC

The cjc-1295 no dac research peptide represents a targeted modification of the naturally occurring GHRH(1-29) sequence. Endogenous GHRH consists of 44 amino acids, but preclinical research demonstrated that the N-terminal 29-amino acid sequence retains full biological activity at the receptor site. To enhance resistance against rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV), four specific amino acid substitutions were engineered into the standard GRF 1-29 peptide backbone.

These strategic modifications include D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27. The resulting tetrasubstituted structure dramatically increases plasma stability relative to native GHRH(1-29) while preserving high binding affinity for the growth hormone-releasing hormone receptor (GHRHR). Unlike its counterpart modified with the Drug Affinity Complex (DAC), CJC-1295 No DAC does not covalently bind to circulating serum albumin, resulting in a distinct half-life profile suitable for investigating rapid, physiological GH pulses in animal and cell culture models.

Mechanism of Action: GHRH Receptor Activation and GH Secretion

In vitro and animal models show that CJC-1295 No DAC functions as a selective agonist at the human GHRH receptor, a G-protein-coupled receptor (GPCR) expressed primarily on anterior pituitary somatotrophs. Activation of GHRHR triggers the Gs alpha subunit, stimulating transmembrane adenylyl cyclase to convert ATP into cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP concentrations activate protein kinase A (PKA), leading to the phosphorylation of L-type voltage-gated calcium channels and influx of extracellular calcium.

This intracellular signal cascade prompts exocytosis of stored growth hormone granules from somatotroph cells. Additionally, the cAMP-PKA pathway activates CREB (cAMP response element-binding protein), driving gene transcription for GH synthesis. Preclinical studies suggest that because CJC-1295 No DAC lacks the albumin-binding moiety, its interaction with pituitary receptors produces discrete, elevated pulses of growth hormone rather than continuous baseline elevation, mirroring normal physiological secretion patterns.

Downstream Signaling: The IGF-1 Axis and Tissue Repair Research

Growth hormone released following GHRH receptor stimulation travels via systemic circulation to hepatocytes and peripheral tissues, where it binds to growth hormone receptors (GHR). Activation of hepatic GHR initiates the JAK2/STAT5 signaling pathway, inducing the synthesis and secretion of insulin-like growth factor 1 (IGF-1). In cellular and animal research models, IGF-1 serves as a primary mediator of cell proliferation, protein translation, extracellular matrix deposition, and somatic growth.

In vitro and preclinical animal models evaluating tissue repair demonstrate that elevated local and systemic IGF-1 levels correlate with accelerated fibroblast migration, increased collagen cross-linking, and enhanced satellite cell activation in skeletal muscle tissue. Researchers examining musculoskeletal repair, osteoblast activity, and cellular regeneration utilize GHRH analogs like CJC-1295 No DAC to explore how regulated, non-toxic stimulation of the GH/IGF-1 axis influences wound healing and metabolic turnover in experimental settings.

Pharmacokinetics: Distinguishing CJC-1295 No DAC from CJC-1295 DAC

A critical distinction in research peptides lies between CJC-1295 No DAC (Modified GRF 1-29) and CJC-1295 with DAC. The Drug Affinity Complex (DAC) is a reactive maleimido derivative attached to the Lysine residue at position 30. In vivo, the maleimide group forms a covalent bond with the free thiol group on circulating serum albumin, extending the terminal elimination half-life from approximately 30 minutes to over 6 to 8 days in experimental models.

Conversely, CJC-1295 No DAC lacks this maleimide linker. In preclinical pharmacokinetic assays, CJC-1295 No DAC exhibits a biological half-life of approximately 15 to 30 minutes following administration in animal subjects, producing a sharp, transient spike in serum GH levels followed by a rapid clearance phase. Researchers seeking to study natural, episodic GH pulsatility without inducing continuous GHRH receptor occupancy preferentially select the No DAC variant for controlled laboratory protocols.

Synergistic Preclinical Dynamics: Co-Administration with GHRPs

In experimental endocrinology, researchers frequently investigate the synergistic response achieved by combining GHRH analogs with growth hormone secretagogues (GHS) or growth hormone-releasing peptides (GHRPs). While GHRH analogs act on the GHRH receptor to stimulate cAMP production, ghrelin receptor agonists such as ipamorelin act via the growth hormone secretagogue receptor (GHS-R1a), activating the phospholipase C (PLC) and inositol trisphosphate (IP3) signaling pathways.

In vitro somatotroph cultures and rodent models demonstrate that simultaneous activation of GHRHR (cAMP-dependent) and GHS-R1a (IP3/calcium-dependent) produces a synergistic release of GH that significantly exceeds the sum of individual peptide responses. Investigating co-administered peptides allows laboratory teams to analyze maximal somatotroph secretory capacity and refractory period dynamics under varying receptor stoichiometry.

Comparative Analysis: GHRH Analogs and Secretagogues

To select the appropriate tool for secretagogue studies, investigators compare CJC-1295 No DAC against other GHRH receptor ligands and ghrelin mimetics. While native GHRH(1-29) is rapidly degraded by plasma peptidases within 3–5 minutes, CJC-1295 No DAC incorporates tetrasubstitutions that extend its functional window while maintaining physiological pulse kinetics.

When evaluating the broader class of secretagogues, researchers contrast cjc-1295 dac (extended half-life, continuous elevation), sermorelin (unmodified GRF 1-29, rapid clearance), tesamorelin (trans-3-hexenoic acid modified GHRH 1-44 with enhanced lipolytic activity), and ipamorelin (selective ghrelin receptor agonist). A comparative summary of these laboratory research compounds is outlined below:

• **CJC-1295 No DAC**: Tetrasubstituted GRF 1-29; high GHRH receptor selectivity; short half-life (~15–30 min); ideal for pulsatile GH models. • **CJC-1295 DAC**: Tetrasubstituted GRF 1-30 with maleimide linker; extended half-life (~6–8 days); produces sustained baseline elevation. • **Sermorelin**: Native sequence GHRH(1-29); unmodified N-terminus; rapidly degraded by DPP-IV (~5–10 min half-life). • **Tesamorelin**: Hexenoyl-GHRH(1-44); targeted for hepatic lipid metabolism and visceral adipose degradation studies. • **Ipamorelin**: Pentapeptide GHS-R1a agonist; selective GH pulse generator without raising ACTH, cortisol, or prolactin.

Laboratory Reconstitution and Solubilization Protocols

CJC-1295 No DAC is supplied as a sterile, lyophilized cake or powder to ensure chemical stability during transit and storage. Reconstitution must be performed under aseptic conditions within a laminar flow hood or biosafety cabinet to avoid microbial or particulate contamination.

For standard laboratory assays, bacteriostatic water containing 0.9% benzyl alcohol or sterile deionized water is introduced slowly along the glass wall of the vial. Direct, high-velocity jetting onto the lyophilized pellet should be avoided to prevent mechanical shearing of the peptide chain. Swirl the vial gently in a circular motion until complete dissolution occurs. Vortexing or vigorous shaking is strictly discouraged, as atmospheric oxygen entrainment and physical agitation can cause peptide aggregation or denaturation.

Storage Conditions, Stability, and Lyophilization Integrity

Lyophilized CJC-1295 No DAC remains stable at -20°C or -80°C for extended periods when protected from atmospheric moisture and UV light. Repeated freeze-thaw cycles must be strictly avoided, as water ice crystal formation during ambient transitions induces peptide bond cleavage and irreversible precipitation.

Once reconstituted, aqueous solution aliquots should be stored at 2°C to 8°C and utilized within a defined experimental timeframe. Degradation pathways for GHRH analogs in solution primarily involve deamidation of asparagine residues and oxidation of methionine residues. To review comprehensive handling specifications or source high-purity lots for experimental design, researchers can access our complete catalog of all peptides or establish institutional supply lines via our wholesale portal.

Analytical Verification Standards: HPLC, MS, and Endotoxin Control

To guarantee experimental reproducibility and prevent artifactual data in cell culture or animal assays, research compounds must meet strict purity and identity criteria. PX1 Research subjects every synthesis lot of CJC-1295 No DAC to comprehensive analytical testing prior to release.

Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) verifies physical purity, ensuring the peptide content exceeds 98.0% with minimal synthesis truncated sequences or side-chain impurities. Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) or Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact molecular weight (3367.9 Da) and amino acid composition. Furthermore, Limulus Amebocyte Lysate (LAL) testing is performed to quantify bacterial endotoxins, guaranteeing levels remain strictly below regulatory thresholds to prevent non-specific inflammatory responses in sensitive cell lines.

PX1 Research Quality Assurance and Institutional Procurement

PX1 Research manufactures all research peptides in US-based, GMP-compliant facilities adhering to ISO 9001 and ISO 17025 laboratory quality management systems. Every product shipped is accompanied by a lot-specific Certificate of Analysis (COA) detailing RP-HPLC chromatograms, mass spectra, and endotoxin assay results.

Researchers and procurement managers evaluating suppliers can inspect our complete research library for empirical documentation and technical whitepapers. Institutional buyers seeking bulk allocations or dedicated analytical validation reports can utilize our streamlined ordering system, backed by fast dispatch from our California and Arizona distribution centers.